0001093557-24-000062.txt : 20240410 0001093557-24-000062.hdr.sgml : 20240410 20240410160459 ACCESSION NUMBER: 0001093557-24-000062 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240408 FILED AS OF DATE: 20240410 DATE AS OF CHANGE: 20240410 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SAYER KEVIN R CENTRAL INDEX KEY: 0001286858 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51222 FILM NUMBER: 24835773 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: DEXCOM INC CENTRAL INDEX KEY: 0001093557 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 330857544 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8582000200 MAIL ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 edgardoc.xml PRIMARY DOCUMENT X0508 4 2024-04-08 0 0001093557 DEXCOM INC DXCM 0001286858 SAYER KEVIN R 6340 SEQUENCE DRIVE SAN DIEGO CA 92121 1 1 0 0 President CEO and Chairman 1 Common Stock 2024-04-08 4 S 0 27272 137.9616 D 306254 D Common Stock 2024-04-08 4 S 0 22361 138.7079 D 283893 D On December 12, 2023, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. This transaction was executed in multiple trades at prices ranging from $137.61 to $138.36. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. Included in this number are 109,641 unvested restricted stock units, 51,692 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 36,281 of which were granted on March 9, 2023 and shall vest through March 8, 2026, 21,668 of which were granted on March 8, 2022 and shall vest through March 8, 2025. This transaction was executed in multiple trades at prices ranging from $138.385 to $139.15. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. By: /s/ Jereme M Sylvain For: Kevin R Sayer 2024-04-10